Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
08
04
2019
accepted:
26
09
2019
pubmed:
5
10
2019
medline:
28
4
2021
entrez:
5
10
2019
Statut:
ppublish
Résumé
In some settings, cancer cells responding to treatment undergo an immunogenic form of cell death that is associated with the abundant emission of danger signals in the form of damage-associated molecular patterns. Accumulating preclinical and clinical evidence indicates that danger signals play a crucial role in the (re-)activation of antitumor immune responses
Identifiants
pubmed: 31582537
pii: haematol.2019.223933
doi: 10.3324/haematol.2019.223933
pmc: PMC7327638
doi:
Substances chimiques
Calreticulin
0
Interleukin-15
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1868-1878Informations de copyright
Copyright© 2020 Ferrata Storti Foundation.
Références
Cancer Cell. 2018 Sep 10;34(3):361-378
pubmed: 30216189
Blood. 2007 Jun 1;109(11):4839-45
pubmed: 17299090
Oncoimmunology. 2017 Jan 13;6(3):e1279372
pubmed: 28405503
World J Gastroenterol. 2010 May 21;16(19):2428-34
pubmed: 20480531
Pharmacol Ther. 2017 Feb;170:73-79
pubmed: 27777088
J Immunol. 2015 Sep 15;195(6):2580-90
pubmed: 26246143
EMBO J. 2009 Mar 4;28(5):578-90
pubmed: 19165151
Leuk Res. 2008 Apr;32(4):527-34
pubmed: 17543383
Cancer Res. 2016 Apr 1;76(7):1746-56
pubmed: 26842877
Front Immunol. 2015 Aug 07;6:402
pubmed: 26300886
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232229
Cancer Res. 2005 Jun 15;65(12):5238-47
pubmed: 15958569
J Immunol. 2001 Aug 1;167(3):1179-87
pubmed: 11466332
Oncoimmunology. 2017 Jan 10;6(4):e1278332
pubmed: 28507789
PLoS Pathog. 2014 Mar 20;10(3):e1004011
pubmed: 24651485
Int J Cancer. 2000 Dec 1;88(5):791-7
pubmed: 11072250
Nat Rev Immunol. 2017 Oct;17(10):608-620
pubmed: 28669986
Front Immunol. 2017 Sep 25;8:1194
pubmed: 28993779
Trends Immunol. 2004 Jun;25(6):328-33
pubmed: 15145323
Oncotarget. 2015 Jun 10;6(16):14360-73
pubmed: 25961317
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Blood. 2016 Dec 29;128(26):3113-3124
pubmed: 27802968
Cell Death Dis. 2010 Dec 02;1:e104
pubmed: 21368877
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Cell Death Differ. 2017 May;24(5):832-843
pubmed: 28234357
Nat Rev Mol Cell Biol. 2018 Nov;19(11):731-745
pubmed: 30305710
Trends Immunol. 2013 Feb;34(2):67-73
pubmed: 23122052
Cancer Cell. 2017 Aug 14;32(2):135-154
pubmed: 28810142
Nat Med. 2015 Oct;21(10):1128-38
pubmed: 26444637
Nat Rev Immunol. 2005 Feb;5(2):112-24
pubmed: 15688039
Int J Cancer. 2014 Sep 1;135(5):1165-77
pubmed: 24500981
Cell Stress Chaperones. 2005 Summer;10(2):136-46
pubmed: 16038410
Nat Med. 2011 Jun;17(6):700-7
pubmed: 21552268
J Immunol Res. 2018 Sep 3;2018:6248590
pubmed: 30255106